D-Wave Quantum at a Crossroads: A $100 Million Government Nod and a Market That’s Still Waiting

The story of D-Wave Quantum right now is a tale of two very different kinds of validation. One comes from Washington, where the US Commerce Department has pledged to inject $100 million directly into the company in exchange for equity. The other is playing out in the public markets, where a rival’s Nasdaq debut sent the stock tumbling and left investors questioning the sector’s near-term prospects.

It’s a tense moment for a company that closed Friday at €20.20 — down roughly 16% since the start of the year and still sitting just below its 200-day moving average of €20.88. The 52-week high of €38.48, hit in October 2025, now looks distant, almost 48% above the current price. The market is clearly not pricing in the government’s interest just yet.

A State-Backed Equity Stake Unlike Any Other

What sets the CHIPS and Science Act pledge apart from a typical research grant is the structure. D-Wave would issue shares directly to the Department of Commerce, making Uncle Sam a shareholder rather than a funding partner. That’s a sovereign investor sitting on the cap table — a level of endorsement that goes well beyond a standard contract.

On top of that, D-Wave has been awarded a second phase of the SQFab project, a defense-related initiative worth $25 million that aims to move nanofabrication from lab to factory. For a company with a market cap around €7.5 billion, these mandates aren’t just cash — they’re credibility. But the formal closing of the CHIPS Act transaction still hangs in the air as a letter of intent, meaning the full institutional re-rating is on hold until pen meets paper.

The Quantinuum Shockwave and London’s Test

The negative pressure arrived in late May when Quantinuum went public on the Nasdaq, triggering a sector-wide selloff. Rivals IonQ and Rigetti Computing saw double-digit percentage drops, and D-Wave lost roughly 6% in the immediate aftermath. The event highlighted just how sensitive quantum stocks are to competitive noise — every IPO in the space is a fresh reason for skittish investors to rotate out.

That background makes next Tuesday’s Qubits Europe conference in London all the more pivotal. D-Wave is bringing customers and researchers together to showcase commercial applications, hoping to demonstrate that its Quantum Annealing technology is solving real optimization problems today, not just promising theoretical breakthroughs. The UK and Europe are pouring money into quantum infrastructure, and the event gives management a chance to lock in new partnerships in a region that matters.

Should investors sell immediately? Or is it worth buying D-Wave Quantum?

Two Tracks, One Destination

D-Wave is no longer positioning itself as a one-technology company. In June, it unveiled a gate-model roadmap that targets 100 logical qubits and over a million operations by 2032. That’s a long-term bet on universal quantum computing. But the existing annealing platform remains the commercial engine — it’s generating revenue from enterprise clients now, while the gate-model work runs in parallel.

This dual approach was accompanied by board changes at the annual meeting. Sharon Holt, who joined the board in late 2024, took over as chair from Steven M. West. New faces also appeared on the compensation and cybersecurity committees — a signal that the governance structure is being aligned for the next phase of growth.

The Technical Picture and the Analyst View

At €20.20, the stock is roughly 8% above its 50-day moving average but still below the longer-term 200-day line. The RSI of 47 suggests no extreme readings — buyers and sellers are evenly matched. Volatility, however, is extreme; the annualized 30-day figure of over 139% is a reminder that this is not a stock for the faint-hearted.

Wall Street analysts remain broadly optimistic despite the recent pullback. B. Riley raised its price target from $36 to $40, citing progress on error correction. Stifel has a buy rating and a $35 target, pointing to D-Wave’s transformation into a full-stack quantum provider. The consensus of eleven analysts sits at $40 on the primary target, while a broader consensus number of $31.50 still implies roughly 56% upside from the current level. But such targets have a notoriously short shelf life in the quantum space, where sentiment can shift on a single headline.

What Moves Next

The immediate catalyst is London. If the management team can unveil concrete customer projects at Qubits Europe, the market may start taking the analyst price forecasts seriously. The larger trigger, however, is the formalization of the CHIPS Act stake. Once the Commerce Department’s $100 million equity purchase becomes binding, the company’s balance sheet — and its perception among institutional investors — changes fundamentally. Right now, both events are placeholders on a calendar. By this time next week, one of them will have delivered actual news.